Cargando…

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism

Postthrombotic syndrome (PTS) is a frequent complication of venous thromboembolism (VTE). Using MarketScan claims data from January 2012 to June 2015, we identified adults with a primary diagnosis code for VTE during a hospitalization/emergency department visit, ≥6 months of insurance coverage prior...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coleman, Craig I., Beyer-Westendorf, Jan, Bunz, Thomas J., Mahan, Charles E., Spyropoulos, Alex C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714693/ https://www.ncbi.nlm.nih.gov/pubmed/29514466 http://dx.doi.org/10.1177/1076029618758955

Ejemplares similares

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Postthrombotic Syndrome: Surgical Possibilities
por: Khanna, Ajay K., et al.
Publicado: (2012)

Interventional treatment of postthrombotic syndrome
por: Jalaie, H., et al.
Publicado: (2016)

COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
por: Müller, Stephanie, et al.
Publicado: (2022)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Betrixaban for prevention of venous thromboembolism in acute medically ill patients
por: Beyer-Westendorf, Jan, et al.
Publicado: (2018)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Venous Stenting for Postthrombotic Iliocaval Venous Obstructive Disease: Clinical Efficacy and Mid-term Outcomes
por: Hoshino, Yuji, et al.
Publicado: (2022)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Does Catheter-Directed Thrombolysis Prevent Postthrombotic Syndrome?
por: Kim, Young-Ah, et al.
Publicado: (2018)

Recanalization of an Occluded Vena Cava Filter and Iliac Veins with Kissing Stents to Treat Postthrombotic Syndrome with a Venous Stasis Ulcer
por: Ko, Hyunmin, et al.
Publicado: (2020)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban
por: Piati, Polyana Klomfass, et al.
Publicado: (2019)

Cutaneous Paecilomyces infection in an immunocompromised patient in the setting of postthrombotic syndrome successfully treated with posaconazole
por: Martinez, Edgar, et al.
Publicado: (2020)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

The management of venous thromboembolism in hospitalized patients with COVID-19
por: Spyropoulos, Alex C.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States
por: Berger, Jeffrey S., et al.
Publicado: (2022)

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
por: Li, Ke Xuan, et al.
Publicado: (2021)

New and known predictors of the postthrombotic syndrome: A subanalysis of the ATTRACT trial
por: Rinfret, Félix, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tu7g5p60aospvq3ma4drsqoq0s